TL;DR
Get beauty and skincare favorites delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
UK sales of hair-loss products grew 32% in the year to the end of August, according to Worldpanel by Numerator, as use of GLP-1 medicines also increased. A BMJ-published study identified an association between GLP-1 drugs and higher hair-loss risk, but researchers described the absolute risk as low; the available report does not establish that the drugs directly cause hair loss.
UK sales of hair-loss products rose 32% in the year to the end of August, while use of GLP-1 medicines continued to grow, according to figures cited by Cosmetics Business. The development matters to consumers using drugs such as semaglutide and tirzepatide because a study published in the British Medical Journal (BMJ) identified an association with increased hair-loss risk, although researchers said the absolute risk is low.
Worldpanel by Numerator estimates that hair-loss product sales in the UK increased 32% over the 12 months ending in August. The figures cover sales, not the number of people experiencing hair loss, and the report does not provide product-by-product data or a breakdown of how much growth came from GLP-1 users. It describes increased medicine use as a likely factor behind the market growth, rather than proving a direct cause.
The same research firm’s household estimates show the share of households in Great Britain using GLP-1 drugs at 2.3% in 2024, 4.1% in 2025 and 6.3% in 2026. Those percentages are household-use estimates, not the share of individuals taking a medicine. The report does not specify the exact collection dates or methodology behind the figures.
The cosmetics industry report also cites a recent BMJ-published study that found a link between GLP-1 medicines and increased risk of hair loss. It does not provide the study’s sample size, measured risk, or details on how the researchers accounted for other possible causes. The report says Novo Nordisk, maker of Ozempic, has announced an intention to enter the hair-loss treatment market; it gives no product, development or launch details.
A New Audience for Hair-Loss Care
Rising use of medicines associated with weight loss may be bringing more attention to hair thinning and shedding, giving hair-care companies a potential new customer group. The 32% sales increase indicates growing demand across the UK market, but the available figures do not show whether GLP-1 users account for that increase or whether consumers are buying products preventively.
For people taking these medicines, the study’s reported association is relevant when weighing possible side effects, but it is not proof that a GLP-1 drug caused an individual’s hair loss. The source says researchers assessed the absolute risk as low. Hair loss can have multiple causes, and the reported material does not establish how much of the observed risk is attributable to the medicines themselves.
Novo Nordisk’s stated interest in hair-loss treatment also signals a possible commercial response from a company already known for GLP-1 medicines. Any potential treatment remains unspecified in the source, so the announcement does not establish that a new therapy is available or that it would address medicine-associated shedding.
Products Worth Considering
Therabody SmartGoggles 2nd Gen Heated Eye and Temple Massager
Bowflex PR1000 Home Gym
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
From Weight-Loss Drugs to Hair Care
Products marketed to volumise, thicken or strengthen hair, as well as treatments for hair loss, predate the current expansion of GLP-1 medicines. The change described by Cosmetics Business is the growing demand behind those products as semaglutide and tirzepatide use becomes more common. Ozempic and Wegovy are semaglutide brands; Mounjaro contains tirzepatide.
Reports of hair loss among people using GLP-1 drugs were initially described as anecdotal. The BMJ-published research cited in the report adds evidence of an association, but the source excerpt does not provide enough information to assess the study design or determine whether it establishes causation. Cosmetics Business connects this emerging research and increased medicine use with recent UK sales data, while leaving the precise relationship between them unquantified.
“The absolute risk is low.”
— Researchers in the BMJ-published study, as summarized by Cosmetics Business
What the Evidence Cannot Yet Show
The source material does not include the BMJ study’s methods, participant numbers, effect size or analysis of other factors that can contribute to hair loss. The reported association does not establish that GLP-1 medicines directly cause shedding, and the researchers’ assessment that absolute risk is low is not accompanied by a numerical estimate in the excerpt.
It is also unclear how much GLP-1 use contributed to the 32% rise in hair-loss product sales. The sales figure covers the UK market overall, while the medicine-use estimates cover Great Britain households. The source does not provide evidence connecting individual medicine use with individual purchases or hair-loss outcomes.
Novo Nordisk’s reported intention to enter the hair-loss treatment market is not described in detail. The material does not identify a product, its development stage, intended use, evidence base or expected availability.
Evidence and Product Plans Ahead
Further details on the BMJ research would help readers assess the size and limits of the reported association, including the study population, methods and absolute risk estimates. Updated market data could also clarify whether hair-loss product sales continue to rise and whether researchers or retailers can link that demand more directly to GLP-1 use.
For Novo Nordisk, the next visible developments would be details on what its hair-loss treatment plans involve and whether any product will enter clinical testing or development. No launch timetable or treatment details are given in the available report. People experiencing hair loss while using a prescription medicine should discuss symptoms and treatment choices with a qualified health professional rather than treating market claims as medical advice.
Key Questions
What is the main development in this report?
UK hair-loss product sales rose 32% in the year to the end of August, while GLP-1 use increased. The report says a BMJ-published study found an association between these medicines and increased hair-loss risk.
Does the study prove GLP-1 drugs cause hair loss?
No. The source describes a link or association, not proof of direct causation. It also says researchers assessed the absolute risk as low; the excerpt does not give a numerical risk estimate.
How common is GLP-1 use in Great Britain, according to the figures?
Worldpanel by Numerator estimates that the share of households using GLP-1 medicines rose from 2.3% in 2024 to 4.1% in 2025 and 6.3% in 2026. These are household estimates, not percentages of individual people.
Why are hair-loss products gaining attention?
Cosmetics Business reports that sales grew 32% in the year to the end of August and says rising GLP-1 use may be contributing. The available figures do not establish how much of the sales growth is linked to medicine use.
Is Novo Nordisk launching a hair-loss treatment?
The report says the Ozempic maker has announced an intention to enter the hair-loss treatment market. It provides no named product, development details or launch date, so availability is not established.
Source: cosmeticsbusiness.com
